Given that RSV induces a TSLP-dependent, IL-13–producing ILC2 response in mice and that IL-13 promotes airway obstruction, it is intriguing to consider the therapeutic potential of an anti-TSLP mAb for treating severe RSV infection. This evidence concerns the gene IL13 and Airway obstruction.